WuXi Biologics Recognized as Both Industry and Regional Top-Rated Company by Sustainalytics
Shanghai, China, Feb. 17, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), is recognized as both 2023 Industry and Regional Top-Rated ESG Company by Sustainalytics. This marks the third consecutive year the company has been awarded by the global provider of Environmental, Social and Governance (ESG) risk ratings.
Sustainalytics assesses companies based on their ability to manage ESG risks. Its multi-dimensional way of measuring ESG risks combines the concepts of management and exposure. This year the ratings cover more than 15,000 companies across 42 industries worldwide, and assess WuXi Biologics as “Low Risk” level. WuXi Biologics ranks top 2% in a total of nearly 1,000 assessed companies of pharmaceutical-related industry, and also receives a ranking of Asia/Pacific “Regional Top-Rated”.
Dr. Chris Chen, WuXi Biologics’ CEO and Chairman of the company’s ESG Committee, commented, “We are very proud to be an Industry Top-Rated company and Regional Top-Rated company, which validates our sustainability efforts to ESG strategy and practice. Our ESG performance also shows WuXi Biologics’ commitment to creating greater value for our stakeholders. WuXi Biologics will continue to implement ESG strategy and to enable global partners to discover, develop, and manufacture biologics for the benefit of patients worldwide.”
WuXi Biologics has set the ESG criteria as an integral part of its business strategy and operations. The company’s ESG achievements have been well recognized by multiple major global rating agencies, including MSCI, S&P Global, CDP and EcoVadis.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com